Paul Tudor Jones’s BioAtla BCAB Stock Holding History

Paul Tudor Jones’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-156	Closed	-$230K	–	2396
2021 Q3	$230K	Buy	+156	New	+$304K	﹤0.01%	2222

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Paul Tudor Jones's BCAB Position: Q4 2021 in Review

Paul Tudor Jones sold out of BioAtla (BCAB) in Q4 2021, closing a stake of 156 shares — an estimated $230K sold.

Paul Tudor Jones first reported a position in BCAB in Q3 2021 and held it in 1 quarter. The position peaked at $230K in Q3 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2021.

Paul Tudor Jones reported no remaining BioAtla position as of Q4 2021 after selling out during the quarter.
Paul Tudor Jones sold 156 BioAtla shares in Q4 2021, an estimated $230K.
Paul Tudor Jones first reported a position in BioAtla in Q3 2021 and held it in 1 quarter.
Paul Tudor Jones's BioAtla position peaked at $230K in Q3 2021.
79 funds tracked by Wall St. Rank held BioAtla as of Q4 2021.

Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.